Comparative study of safety and efficacy of intravenous iron sucrose and ferric carboxymaltose in the treatment of postpartum iron deficiency anaemia

Alpana Singh*, Ramadevi Yerragudi

Department of Obstetrics & Gynaecology, Malla Reddy Institute Of Medical Sciences, Hyderabad, Telangana, India

Received: 02 February 2016
Accepted: 01 March 2016

*Correspondence:
Dr. Alpana Singh,
E-mail: dralpanasingh21@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Anaemia is the most commonly encountered and reversible medical problem during pregnancy and postpartum period. It adversely affects the health of both mother and foetus. Oral iron therapy has many disadvantages-poor compliance and gastrointestinal side effects lead the list. Intravenous iron is an effective alternative in correcting anaemia and restoring iron stores. The objective of this study was to evaluate the safety and efficacy of intravenous iron sucrose and ferric carboxymaltose in treatment of post partum anaemia and compare the rise in Hb% and serum ferritin stores after treatment with IV iron sucrose and ferric carboxymaltose.

Methods: This was a prospective analytical study conducted on 100 postpartum patients in a medical college and research centre in South India. Patients for study were selected from the postnatal ward, having haemoglobin concentration of <10gm/dl and iron deficiency anaemia as the aetiology. All the selected patients were randomly categorized into two groups to receive intravenous iron sucrose and ferric carboxymaltose. The tolerability and side effects of both the injections were noted. Hb% and serum ferritin were repeated 2 weeks and 6 weeks after treatment and results analyzed.

Results: The increment in Hb% in IV iron sucrose group after 2 and 6 weeks was 9.69±0.49 gm/dl and 11.28±0.53 gm/dl respectively. Ferric carboxymaltose showed 9.8±0.43 gm/dl and 12.22±0.43 gm/dl rise in Hb% at the same time interval. Serum ferritin showed a significant increase in IV ferric carboxymaltose group as compared to IV iron sucrose at 2 and 6 weeks (p=0.049; p=0.023).

Conclusions: Ferric carboxymaltose has a greater safety profile (p) and offers faster elevation of haemoglobin and iron stores with less hospital stay as compared to iron sucrose.

Keywords: Iron sucrose, Ferric carboxymaltose, Postpartum anaemia, Haemoglobin, Ferritin

INTRODUCTION

Anaemia is most commonly encountered and easily reversible health problem during pregnancy and postpartum period. It is a major cause of concern as besides many adverse effects on mother and foetus, it contributes significantly to high maternal mortality and morbidity. The most common cause of anaemia during child bearing period is iron deficiency. Iron nutritional status depends on long term iron balance -ingestion of adequate amount of iron in the diet and its absorption from the gut vis-à-vis consumption/loss in conditions of overt or covert blood loss and removal of old and effete red blood cells. Iron deficiency may result from inadequate dietary intake, achlorhydria or excessive ingestion of proton pump inhibitors, parasitic infestations, chronic infections and repeated pregnancies. Iron supplementation of antenatal patients is a basic tenet of
antenatal care programmes in numerous developing and underdeveloped nations.

Postpartum anaemia is defined as haemoglobin of less than 10 gm% during the postpartum period. The prevalence of postpartum anaemia varies from 4 - 27%. Chronic iron deficiency due to inadequate intake/ lack of iron supplementation during pregnancy, repeated pregnancies and postpartum haemorrhage are important causes of postpartum anaemia. Postpartum anaemia is associated with anxiety, depression and prolonged hospital stay. It imposes a substantial disease burden during the critical period of maternal – infant interaction and may give rise to lasting developmental deficits in infant of affected mothers.

The standard treatment of postpartum anaemia is oral iron supplementation with blood transfusion reserved for severe anaemia. Treatment with high doses of oral iron has poor compliance and produces lot of side effects including gastric irritation, nausea, diarrhoea and constipation. Parenteral iron scores over oral therapy by providing a faster and more effective correction of total iron deficit sans gastrointestinal side effects.

Two types of intravenous (IV) preparations available are IV iron sucrose and IV ferric carboxymaltose. IV iron sucrose is safe, effective and economical. Reported incidence of adverse reactions with IV iron sucrose is less as compared to older iron preparations (iron dextran, iron sorbitol), but it requires multiple doses and prolonged infusion time. Ferric carboxymaltose is a dextran free iron formulation, has neutral pH and physiological osmolarity. It can be administered in high single dose without the risk of severe anaphylactic reactions. In our study, we compare the tolerability and efficacy of IV iron sucrose and IV ferric carboxymaltose in treatment of postpartum iron deficiency anaemia.

METHODS

This was a prospective analytical study conducted on 100 postpartum patients in a tertiary hospital from November 2014 to October 2015. Approval from the ethics committee was obtained before starting the study. Patients for study were selected from the postnatal ward, having haemoglobin concentration of <10gm/dl. Patients with haemolytic disorders, megaloblastic anaemia, aplastic anaemia, previous surgeries of intestinal resections/bypass, chronic renal disease, liver disease were excluded from the study. After careful history taking and examinations, a complete blood picture, serum Ferritin and peripheral smear were done to diagnose iron deficiency anaemia. Those with Hb% ≤6gm/dl were considered for blood transfusion. All the selected patients having iron deficiency anaemia were randomly categorized into two groups to receive intravenous iron sucrose and ferric carboxymaltose. Required doses of iron was calculated by the following formula –

\[ 2.21 \times \text{body weight in kg} \times \text{Hb deficit} + 500 \] (Hb deficit = Target Hb – actual Hb)

Target Hb% in postpartum women taken was 12g/dl; 500mg is for body stores.

Iron sucrose was given as intravenous infusion of 200mg of elemental iron diluted in 100ml of 0.9% normal saline over 30 minutes, repeated on alternate day.

Ferric carboxymaltose was administered as intravenous infusion of maximum single dose of 1000mg diluted in 250ml of 0.9% normal saline over 15 to 30 minutes. Dose was repeated after 1 week if required.

The tolerability and side effects of both the injections were noted. Hb% and serum ferritin were repeated 2 weeks and 6 weeks after treatment and analyzed.

Statistical analysis

Statistical testing was conducted with the statistical package for the social science system (SPSS). Categorical variables are presented as absolute numbers and percentage. Nominal categorical data between the groups were compared using chi2 goodness-to-fit test. The α level was set as p value less than 0.05.

RESULTS

In our prospective study, 100 postpartum patients with iron deficiency anaemia were randomized to receive IV iron sucrose (group 1) or IV ferric carboxymaltose (group 2). Table 1 shows the baseline characteristics of the patients in both the groups. The mean age and mean weight of the patients in iron sucrose group were 23.74±3.94 years and 54.10±7.32 Kg while 23±4.21 years and 54.8±6.91 Kg in ferric carboxymaltose group respectively. Other demographic data like parity and mode of delivery were compared which were found to be clinically insignificant. Baseline haemoglobin concentration, serum ferritin level and total iron deficits were comparable in the two groups.

As shown in Table 2, adverse reactions were milder in both the groups. None of the patients in two groups had severe anaphylactic reactions. Adverse reactions noted were local reactions (swelling, erythema and burning at injection site), vomiting, giddiness and fever. Rate of adverse reaction was 18% in IV iron sucrose group as compared to 6% in ferric carboxymaltose group (p=0.00035).

There was an overall rise in Hb% and serum ferritin level from baseline in both the treatment modalities after 2 and 6 weeks of therapy (Table 3). After 2 weeks the mean Hb% increment was similar in two groups (9.69±0.49 with IV iron sucrose versus 9.80±0.43 with IV ferric carboxymaltose, p = 0.96). But the increment in Hb% with IV ferric carboxymaltose was more than IV iron
sucrose after 6 weeks although statistically insignificant (11.28±0.53 versus 12.22±0.43; p =0.78)

Serum ferritin also showed significant increment after 2 and 6 weeks of therapy in both the modalities and increment was more in IV ferric carboxymaltose group (p =0.049; p= 0.023).

**Table 1: Baseline characteristics of patients in two groups.**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Iron sucrose (N=50)</th>
<th>Ferric carboxymaltose (N=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age</td>
<td>23.74±3.94 years</td>
<td>23±4.21 years</td>
</tr>
<tr>
<td>Mean weight</td>
<td>54.10±7.32Kg</td>
<td>54.8±6.91Kg</td>
</tr>
<tr>
<td>Parity</td>
<td>22(44%)</td>
<td>24(48%)</td>
</tr>
<tr>
<td>Multi</td>
<td>28(56%)</td>
<td>26(52%)</td>
</tr>
<tr>
<td>Type of delivery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginal delivery</td>
<td>32(64%)</td>
<td>29(58%)</td>
</tr>
<tr>
<td>LSCS</td>
<td>18(36%)</td>
<td>21(42%)</td>
</tr>
<tr>
<td>History of PPH</td>
<td>2(4%)</td>
<td>3(6%)</td>
</tr>
<tr>
<td>Base line Hb%</td>
<td>7.98±0.78gm/dl</td>
<td>7.88±0.76gm/dl</td>
</tr>
<tr>
<td>Base line ferritin</td>
<td>13.6±3.08ng/ml</td>
<td>14.46±2.64ng/ml</td>
</tr>
<tr>
<td>Total iron deficit</td>
<td>980.72±120.33mg</td>
<td>988.38±103.61mg</td>
</tr>
</tbody>
</table>

**Table 2: Comparison of adverse effects in both the groups.**

<table>
<thead>
<tr>
<th>Adverse effects</th>
<th>Iron sucrose (N=50)</th>
<th>Ferric carboxymaltose (N=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N  %</td>
<td>N  %</td>
</tr>
<tr>
<td>Local reactions</td>
<td>2  4%</td>
<td>1  2%</td>
</tr>
<tr>
<td>Rashes</td>
<td>0  0%</td>
<td>0  0%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>2  4%</td>
<td>0  0%</td>
</tr>
<tr>
<td>Giddiness/hypotension</td>
<td>3  6%</td>
<td>1  2%</td>
</tr>
<tr>
<td>Fever</td>
<td>2  4%</td>
<td>1  2%</td>
</tr>
<tr>
<td>Breathlessness</td>
<td>0  0%</td>
<td>0  0%</td>
</tr>
<tr>
<td>Total</td>
<td>9  18%</td>
<td>3  6%</td>
</tr>
</tbody>
</table>

**DISCUSSION**

Iron deficiency anaemia during postpartum period is common and deserves special attention due to its potential adverse consequences. It imposes a substantial disease burden during the critical period of maternal – infant interactions. Oral iron therapy is the standard therapy for postpartum iron deficiency anaemia but has poor compliance and tolerance due to its gastrointestinal side effects. Though blood transfusion gives faster recovery, its availability is limited and is associated with serious transfusion reactions and high risk of infections like hepatitis B, C and HIV( although remote). Thus blood transfusions are reserved for the most severe and life threatening situations. Parental iron therapy in this setting seems to be a good and safe alternative.

Present study showed that iron sucrose complex as well as ferric carboxymaltose can be used for correction of postpartum anaemia and restoration of iron stores.

Our study showed that the rise in Hb% and serum ferritin levels was considerable in both the treatment modalities and it was more with ferric carboxymaltose. Similar results were reported by Patel J et al in their study comparing intravenous iron sucrose and intravenous ferric carboxymaltose therapy in iron deficiency anaemia during pregnancy and postpartum period. In another comparative study by Rathod S et al 300 postpartum patients received oral iron, iron sucrose or ferric carboxymaltose for correction of anaemia. Ferric carboxymaltose was found superior to oral iron and iron sucrose in raising haemoglobin and serum ferritin.

Our study shows that both the treatment modalities are well tolerated in postpartum patients. In both the groups the adverse reactions were mild and quickly reversible; although statistically significant reactions were more with IV iron sucrose. There were neither any treatment related severe adverse events nor any serious anaphylactic reaction in both the groups. A similar retrospective observational study was done by Pfenniger A et al to compare the safety and efficacy of intravenous high dose of ferric carboxymaltose and iron sucrose for the treatment of postpartum anaemia. Ferric carboxymaltose was as safe as iron sucrose in the management of postpartum anaemia despite five times of higher doses.

Our study shows that even though administered in high doses, ferric carboxymaltose is well tolerated and more effective than iron sucrose for treatment of post partum iron deficiency anaemia. Compared to iron sucrose, it offers the advantages of administration of high dose of iron at a time, avoids the need of repeated injections, reduces the duration of hospital stay and increases patient comfort.
CONCLUSION

Intravenous ferric carboxymaltose is more effective than intravenous iron sucrose for the correction of postpartum iron deficiency anaemia. It is well tolerated and safe. It should be offered to all postpartum anaemic women to decrease maternal mortality and morbidity.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES


Cite this article as: Singh A, Yerragudi R. Comparative study of safety and efficacy of intravenous iron sucrose and ferric carboxymaltose in the treatment of postpartum iron deficiency anaemia. Int J Reprod Contracept Obstet Gynecol 2016;5:1130-3.